

**Investigation of the inhibitory effects of various drugs on the hepatic
uptake of fexofenadine in humans**

Soichiro Matsushima, Kazuya Maeda, Naoki Ishiguro, Takashi Igarashi and

Yuichi Sugiyama

Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1

Hongo, Bunkyo-ku, Tokyo 113-0033, Japan (S.M., K.M., Y.S.)

Department of Pharmacokinetics and Non-Clinical Safety, Kawanishi Pharma

Research Institute, Nippon Boehringer Ingelheim Co., Ltd. 3-10-1, Yato,

Kawanishi, Hyogo 666-0193, Japan (N.I., T.I.)

Running title: Inhibition of drugs for human hepatic uptake of fexofenadine

Corresponding author: Yuichi Sugiyama, Ph. D.

Address: Department of Molecular Pharmacokinetics, Graduate School of
Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo 113-0033, Japan

Phone: +81-3-5841-4770

Fax: +81-3-5841-4766

E-mail: sugiyama@mol.f.u-tokyo.ac.jp

The number of text pages: 39

The number of figures: 3

The number of Tables: 1

The number of references: 33

The number of words in the:

Abstract. 249 words

Introduction. 744 words

Discussion. 1469 words

Abbreviations: D-MEM, Dulbecco's modified Eagle's medium; EG, estradiol-17 β -D-glucuronide; FEX, fexofenadine; LC/MS, liquid chromatography/mass spectrometry; MDR, multidrug resistance; MRP, multidrug resistance-associated protein; OATP organic anion transporting polypeptide

Abstract

Fexofenadine (FEX), an H₁-receptor antagonist, is mainly eliminated from the liver in an unchanged form. Our previous study suggested that organic anion transporting polypeptide (OATP) 1B3 mainly contributes to the hepatic uptake of FEX (Shimizu et al., 2005). On the other hand, a clinical report demonstrated that a T521C mutation of OATP1B1 increased its plasma AUC (Niemi et al., 2005). Several compounds are reported to have a drug interaction with FEX and some of this may be caused by the inhibition of its hepatic uptake. We checked which transporters are involved in the hepatobiliary transport of FEX by using double transfectants and examined whether clinically reported drug interactions with FEX could be explained by the inhibition of its hepatic uptake. Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate. The inhibitory effects of compounds on FEX uptake in OATP1B3-expressing HEK293 cells were investigated and the maximum degree of increase in plasma AUC of FEX by drug interaction in

clinical situations was estimated. As a result, cyclosporin A and rifampicin were found to have the potential to interact with OATP1B3-mediated uptake at clinical concentrations. From these results, most of the reported drug interaction cannot be explained by the inhibition of hepatic uptake of FEX and different mechanisms such as the inhibition of intestinal efflux should be considered.

Introduction

Fexofenadine (FEX) is an orally active non-sedating histamine H₁-receptor antagonist for the treatment of allergic rhinitis and chronic idiopathic urticaria. After oral administration of [¹⁴C]-FEX to healthy volunteers, 80% of the total dose was recovered in feces and 12% in urine in an unchanged form (Lippert et al., 1995). Since the absolute oral bioavailability of FEX was reported to be 33% (product information, Hoechst Marion, Roussel, Laval, Quebec, Canada), about two-thirds of bioavailable FEX is estimated to be excreted into bile. Accordingly, some drug transporters in the liver are major determinants for the clearance of FEX from systemic blood.

The first step in the process of elimination from the liver is hepatic uptake across the sinusoidal membrane. Accumulated evidence has supported the idea that organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3 play major roles in the hepatic uptake of a wide variety of compounds including endogenous compounds and clinically important drugs such as HMG-CoA reductase inhibitors (statins) (Hagenbuch and Meier, 2004). Shimizu et al. have demonstrated that OATP1B3 mainly contributes to the hepatic uptake of FEX using transporter-expressing HEK293 cells (Shimizu et al., 2005). On the

other hand, a recent clinical report has shown that the genetic polymorphism of OATP1B1 (T521C), which was reported to decrease the transport clearance, increased the plasma AUC of FEX (Niemi et al., 2005). These results suggested that OATP1B1 as well as OATP1B3 is involved in the uptake of FEX into human liver.

Currently, many clinical reports have indicated the drug interaction between FEX and several drugs. Among them, itraconazole (Shon et al., 2005; Shimizu et al., 2006a; Shimizu et al., 2006b; Uno et al., 2006), ketoconazole (Common Technical Document for the Registration of Pharmaceuticals for Human Use), azithromycin (Gupta et al., 2001), erythromycin (Common Technical Document), ritonavir, lopinavir (van Heeswijk et al., 2006), verapamil and probenecid (Yasui-Furukori et al., 2005) increased the plasma AUC of FEX, whereas rifampicin (Hamman et al., 2001) decreased it. One of the possible mechanisms for the increase of its AUC is the inhibition of multidrug resistance 1 (MDR1/ABCB1) in the small intestine by the concomitantly administered compounds. Vectorial transport was reported to be observed in MDR1-expressing LLC-PK1 cells, but not in parent cells (Cvetkovic et al., 1999). Furthermore, after oral administration of FEX, the plasma AUC in *Mdr1a/1b* (-/-)

mice was about 6 times greater than that in FVB mice, whereas after intravenous administration of FEX, there was no difference in the pharmacokinetics of FEX between FVB and *Mdr1a/1b* (-/-) mice, suggesting that *Mdr1a/1b* in the small intestine limits the absorption of FEX (Tahara et al., 2005). Since most of the compounds, which clinically increase the AUC of FEX, have the ability to inhibit MDR1 function, these are likely to increase the intestinal absorption of FEX by the inhibition of MDR1 in the small intestine.

However, considering that the main elimination pathway of FEX is biliary excretion of the unchanged form (Lippert et al., 1995), it is also possible that drug interaction with FEX is caused by the inhibition of its hepatic uptake. Hirano et al. performed detailed investigations to see whether the inhibitory effects of various compounds on OATP1B1-mediated uptake of pitavastatin were clinically relevant (Hirano et al., 2006). However, inhibition potencies of several compounds for OATP1B3-mediated uptake have not yet been clarified.

Therefore, the purpose of this study is to check which transporters are involved in the hepatobiliary transport of FEX and explore which instances can be explained by the inhibition of its hepatic uptake among clinically reported drug interactions. We identified the transporters that can transport FEX by using

double transfectants expressing OATP1B1/multidrug resistance-associated protein (MRP) 2 and OATP1B3/MRP2 (Matsushima et al., 2005). It has often been found that the transcellular transport assay using double transfectants is more sensitive in detecting the transporter-mediated transport compared with the uptake assay in single transporter-expressing cells. Then we checked the inhibitory effects of several compounds that are reported to interact with FEX in clinical situations on the FEX uptake in OATP1B3-expressing HEK293 cells and compared the *in vitro* inhibition constant (K_i) for OATP1B3 with that for OATP1B1 obtained from a previous study (Hirano et al., 2006). Following that, to check whether the inhibition of FEX uptake by several compounds is clinically relevant, we also estimated the maximum degree of increase in plasma AUC of FEX by considering the maximum unbound concentration of inhibitors at the inlet to the liver estimated by an established method for this calculation (Ito et al., 1998).

Materials and Methods

Materials

[³H]-estradiol-17 β -D-glucuronide (EG) (1.6 TBq/mmol) was purchased from Perkin-Elmer Life and Analytical Sciences (Boston, BA). FEX hydrochloride was purchased from Toronto Research Chemicals (North York, ON, Canada). All other chemicals and reagents were of analytical grade and commercially available.

Cell culture

MDCKII cells expressing OATP1B1/MRP2, OATP1B3/MRP2, OATP1B1, OATP1B3, MRP2 and vector-transfected control MDCKII cells have been constructed previously (Matsushima et al., 2005, Ishiguro et al., *submitted*). OATP1B3-expressing HEK293 cells and vector-transfected control cells were also constructed previously (Hirano et al., 2004). Transporter-expressing or vector-transfected MDCKII and HEK293 cells were grown in Dulbecco's modified Eagle's medium (D-MEM) (low glucose) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 1% antibiotic-antimycotic solution (Sigma-Aldrich) at 37 °C under 5% CO₂ and

95% humidity.

Transcellular transport study

The transcellular transport study was performed as reported previously (Matsushima et al., 2005). Briefly, MDCKII cells were grown on Transwell membrane inserts (6.5 mm diameter, 0.4 μm pore size; Corning Coster, Bodenheim, Germany) at confluence for 7 days, and the medium was replaced with D-MEM supplemented with 5 mM sodium butyrate 2 days before the transport study to induce the expression of exogenous transporter. In the transport assay, cells were first washed with Krebs-Henseleit buffer (118 mM NaCl, 23.8 mM NaHCO_3 , 4.83 mM KCl, 0.96 mM KH_2PO_4 , 1.20 mM MgSO_4 , 12.5 mM HEPES, 5.0 mM glucose, and 1.53 mM CaCl_2 adjusted to pH 7.4) at 37 °C and preincubated with Krebs-Henseleit buffer for 10 min. Subsequently, substrates were added in Krebs-Henseleit buffer either to the apical compartment (250 μL) or to the basolateral compartment (1 mL). After a designated period, 50 μL or 100 μL of medium was taken from the opposite side to the added substrate. Using FEX as a substrate, 50 μL aliquots were used for LC/MS quantification as described below. At the end of the experiments, cells

were washed with ice-cold Krebs-Henseleit buffer and solubilized in 500 μ L 0.2 N NaOH. After addition of 100 μ L 1 N HCl, 50 μ L aliquots were used to determine protein concentrations by the Lowry method with bovine serum albumin as a standard.

Uptake study using OATP1B3-expressing HEK293 cells

Cells were seeded in 12-well plates coated with poly-L-lysine/poly-L-ornithine (Sigma) at a density of 1.5×10^5 cells per well. After 2 days, the cell culture medium was replaced with culture medium supplemented with 5 mM sodium butyrate 24 hr before transport assay to induce the expression of exogenous transporters. The transport study was carried out as described previously (Sugiyama et al., 2001). Uptake was initiated by adding Krebs-Henseleit buffer containing FEX. All the procedures were conducted at 37 °C. The uptake was terminated at a designated time by adding ice-cold Krebs-Henseleit buffer after removal of the incubation buffer. Then, cells were washed twice with 1 mL ice-cold buffer, solubilized in 500 μ L 0.2 N NaOH, and kept overnight at room temperature. Using EG as a substrate, aliquots (300 μ L) were transferred to vials after adding 100 μ L 1 N HCl. Using

FEX as a substrate, aliquots (240 μ L) were used for LC/MS quantification as described below. The remaining 50 μ L of the aliquots of cell lysate were used to determine the protein concentration by the Lowry method with bovine serum albumin as a standard.

Quantification of FEX by LC/MS

The aliquots (50 μ L) obtained from the transcellular transport study were precipitated with 200 μ L methanol containing 10 nM midazolam as an internal standard, while the aliquots (240 μ L) obtained from the uptake study were precipitated with 480 μ L methanol containing 50 nM midazolam as an internal standard. After centrifugation (15000 g, 10 min, 4 $^{\circ}$ C) of the mixture, 50 μ L 0.05% formic acid was added to 50 μ L supernatant. The obtained samples were subjected to LC/MS analysis to determine the concentration of FEX. An LC/MS-2010 EV equipped with a Prominence LC system (Shimadzu, Kyoto, Japan) was used for the analysis. The samples were separated on a CAPCELL PAK C18 MG column (3 μ m, 4.6 mm ID, 75 mm, Shiseido, Tokyo, Japan) in binary gradient mode. For the mobile phase, 0.05% formic acid and methanol were used. The methanol concentration was initially 48%, then linearly

increased up to 61.5% over 4.5 min. Finally, the column was re-equilibrated in a methanol concentration of 48% for 3 min. The total run time was 7.5 min. Using this method, FEX was eluted at 4.1 min and midazolam at 2.8 min. In the mass analysis, FEX and midazolam were detected at a mass-to-charge ratio of 502.3 and 326.1 under positive ionization conditions. The interface voltage was 3.5 kV, and the nebulizer gas (N₂) flow was 1.5 L/min. The heat block and curved desolvation line temperatures were 200 and 150 °C, respectively.

Kinetic analyses

Ligand uptake in transporter-expressing cells was expressed as the uptake volume (μL/mg protein), given as the amount associated with the cells divided by its initial concentration in the incubation medium. Transporter-specific uptake was obtained by subtracting the uptake into vector-transfected cells from that into transporter-expressing cells. Inhibition constants (K_i) of a series of compounds could be calculated by the following equation, if the substrate concentration was low enough compared with its K_m value:

$$CL(+I) = \frac{CL}{1 + I/K_i} \quad (\text{Eq. 1})$$

where CL represents the uptake clearance in the absence of inhibitor, CL(+I) represents the uptake clearance in the presence of inhibitor, and I represents the inhibitor concentration. When fitting the data to determine the K_i value, the input data were weighted as the reciprocal of the observed values. The Damping Gauss-Newton method algorithm was used with a MULTI software program (Yamaoka et al., 1981) to fit the data.

Prediction of clinical drug-drug interactions between FEX and various compounds

The degree of inhibition of uptake via OATP1B1 and OATP1B3 in humans was estimated by calculating the following R value, which represents the ratio of the uptake clearance in the absence of inhibitor to that in its presence:

$$R = 1 + \frac{f_u * I_{in,max}}{K_i} \quad (\text{Eq. 2})$$

where f_u represents the protein unbound fraction of the inhibitor in blood, $I_{in,max}$ represents the estimated maximum blood concentration of the inhibitor at the inlet to the liver. K_i value for OATP1B3 was obtained from the present *in vitro* study using OATP1B3-expressing HEK293 cells described above and K_i value

for OATP1B1 is quoted from the previous reports in which pitavastatin is used as a substrate of OATP1B1 (Hirano et al., 2006). For estimation of the R value, $I_{in,max}$ was calculated by the method of Ito et al. (1998) as shown below:

$$I_{in,max} = I_{max} + \frac{F_a * Dose * k_a}{Q_h} \quad (\text{Eq. 3})$$

where I_{max} represents the reported value for the maximum blood concentration of the inhibitor in the systemic circulation in clinical situations, F_a represents the fraction absorbed from intestine of the inhibitor, k_a is the absorption rate constant in the intestine and Q_h represents the hepatic blood flow rate in humans (1610 mL/min) (Ito et al., 1998). To estimate the maximum $I_{in,max}$, F_a was set at 1, k_a was set at 0.1 mL^{-1} [minimum gastric emptying time (10 min)], and the blood-to-plasma concentration ratio was assumed to be 1.

Results

Transcellular Transport of FEX and EG across the MDCKII cell monolayer

The transcellular transport of 5 μ M FEX and 0.1 μ M EG across the MDCKII monolayer was determined. The basal-to-apical transport of FEX was approximately 3.6 times higher than that in the opposite direction in OATP1B1/MRP2 double transfectant (Figure 1 D), whereas no difference in basal-to-apical transcellular transport of FEX could be observed in vector-transfected control cells and single transfectants expressing OATP1B1 or MRP2 (Figure 1 A-C). On the other hand, the basal-to-apical transport of EG was approximately 22 times higher than that in the opposite direction in OATP1B1/MRP2 double transfectants (Figure 1 H), whereas we could not see any basal-to-apical transcellular transport of EG in vector-transfected control cells and single transfectants expressing OATP1B1 or MRP2 (Figure 1 E-G). The basal-to-apical transport of FEX was approximately 2.9 times higher than that in the opposite direction in OATP1B3/MRP2 double transfectant (Figure 2 D), whereas the difference in each directional transport of EG was less than 2 times in vector-transfected control cells and single transfectants expressing OATP1B3 or MRP2 (Figure 2 A-C). As a positive control, the basal-to-apical transport of

EG was approximately 3.0 times higher than that in the opposite direction in OATP1B3/MRP2 double transfectant (Figure 2 H), whereas no significant difference in basal-to-apical transcellular transport of EG was less than 2 times that in vector-transfected control cells and single transfectants expressing OATP1B3 or MRP2 (Figure 2 E-G).

Inhibitory effects of various drugs on OATP1B3-mediated uptake of FEX

The inhibitory effects of various drugs on the uptake of FEX were examined using OATP1B3-expressing HEK293 cells (Figure 3). Some of the drugs we tested were reported to cause drug-drug interactions with FEX in clinical situations. Most of the compounds could inhibit OATP1B3-mediated FEX uptake. On the other hand, even 100 μ M fluconazole, 30 μ M itraconazole and 100 μ M cimetidine did not significantly inhibit the FEX uptake (Figure 3 C, D, N). We also obtained the protein unbound fraction in blood (f_u) from the literature and calculated the estimated maximum concentration at the inlet to the liver ($I_{in,max}$) of the inhibitors. Inhibition constants (K_i) of various compounds for OATP1B3 obtained in the present study and the ratio of the uptake clearance in the absence of inhibitor to that in its presence (R value) are summarized in Table

1. Among several drugs we tested, only the R values of cyclosporin A and rifampicin for OATP1B3-mediated uptake exceeded 2.0. The K_i values of various compounds for OATP1B1 obtained in the previous study and the respective R values are also shown in Table 1 (Hirano et al., 2006). The K_i values of several compounds in the uptake mediated by OATP1B1 and OATP1B3 were not so different. However, the K_i values of clarithromycin and ritonavir for OATP1B1-mediated uptake of pitavastatin were more than 5-fold less compared with that for OATP1B3-mediated uptake of FEX.

Discussion

To check which transporters are involved in the hepatobiliary transport of FEX, we investigated the transcellular transport of FEX using OATP1B1/MRP2 and OATP1B3/MRP2 double transfected cells. Furthermore, to investigate whether the inhibition of FEX hepatic uptake by several drugs is clinically relevant, the inhibition constants (K_i) of several drugs for OATP1B3-mediated FEX uptake obtained from *in vitro* analyses were determined and the maximum degrees of increase in plasma AUC through drug interaction were calculated using estimated maximum protein unbound concentrations of inhibitors at the inlet to the liver.

In the transcellular transport study using double transfected cells, we observed the basal-to-apical vectorial transport of FEX not only in OATP1B3/MRP2- but also in OATP1B1/MRP2-double transfected cells (Figure 1 and 2). Our previous report indicated that OATP1B3 mainly contributes to the hepatic uptake of FEX in humans and that OATP1B1-mediated uptake was not statistically significant though the uptake in OATP1B1-expressing cells was slightly larger compared with that in control cells (Shimizu et al., 2005). The involvement of OATP1B1 in FEX uptake in humans was also supported by the

recent clinical report demonstrating that the genetic polymorphism of OATP1B1 (T521C) increased the plasma concentration of FEX (Niemi et al., 2005). The apparently conflicting results obtained from the present transcellular transport study and the previous uptake study may be caused by the difference in the sensitivity for the detection of the transport. We found that transcellular transport assay using a double transfectant is more sensitive in detecting the transporter-mediated transport compared with an uptake assay in single transporter-expressing cells (Sasaki et al., 2002; Matsushima et al., 2005). For example, the ratio of the basal-to-apical transport of pravastatin to that in the opposite direction was 3.3, while it barely estimates the kinetics of pravastatin transport in OATP1B1-expressing HEK293 cells because of its small OATP1B1-mediated uptake (Matsushima et al., 2005). Therefore, these results suggest a significant contribution of OATP1B1 as well as OATP1B3 to the hepatic uptake of FEX. Further evaluation is required for the determination of the precise relative contribution of OATP1B1 and OATP1B3 to the hepatic uptake of FEX in humans.

The finding presented here is the first demonstration that human MRP2 can recognize FEX as a substrate. MRP2 is expressed in the apical membrane

of the liver, kidney, and intestine. An *in vivo* infusion study using Eisai hyperbilirubinemic rats (EHBR), Mrp2-deficient rats, revealed that Mrp2 is not important for the biliary excretion of FEX (Tahara et al., 2005). However, it is still possible that MRP2 will play an important role in the disposition of FEX in humans. This situation is very similar to that reported for pitavastatin (Hirano et al., 2005). The transcellular transport study using OATP1B1/MRP2 double transfected cells indicated pitavastatin could be transported by MRP2. However, the biliary excretion of pitavastatin in EHBR was not changed compared with control rats. Moreover, there are some reports that show species differences in the expression and function of MRP2 (Ishizuka et al., 1999; Ninomiya et al., 2005; Ninomiya et al., 2006; Takekuma et al., 2007). These may also indicate the species difference in the relative contribution of efflux transporters to the biliary excretion of compounds. The methodology to determine the contribution of efflux transporters in human liver needs to be established by checking the effect of transporter-specific inhibitors on the efflux of compounds in membrane vesicles prepared from human liver or sandwich-cultured human hepatocytes.

Several reports regarding drug-drug interaction with FEX have been

published. It is generally believed that one of the major mechanisms of the reported drug-drug interactions between FEX and concomitantly administered drugs is the inhibition of MDR1-mediated efflux in the small intestine, which plays an important role in limiting the entry of FEX into circulating blood (Tahara et al., 2005). However, some of the reported cases are thought to be caused by mechanisms other than the inhibition of MDR1. A regional perfusion study showed that ketoconazole and verapamil did not have a significant effect on the *in vivo* intestinal absorption of FEX when co-administered or given as a pretreatment in spite of increasing the plasma AUC of FEX (Tannergren et al., 2003). Accordingly, the involvement of other mechanisms in addition to the inhibition of MDR1 has been supposed. One of the candidate mechanisms is considered to reduce the hepatic uptake clearance because the major route of FEX elimination is biliary excretion of the unchanged form. Since FEX is barely metabolized, the apparent intrinsic hepatic clearance is described as follows:

$$CL_{int,h} = CL_{uptake} * \frac{CL_{excretion}}{CL_{efflux} + CL_{excretion}} \quad (\text{Eq. 4})$$

where $CL_{int,h}$, represents the apparent intrinsic hepatic clearance, CL_{uptake} , the hepatic uptake clearance, $CL_{excretion}$, the biliary excretion clearance, and CL_{efflux} , the backflux clearance from liver to blood. According to Eq. 4, the change in

the hepatic uptake clearance always directly affects the overall intrinsic hepatic clearance. The present study indicates that both OATP1B1 and OATP1B3 contribute to the hepatic uptake of FEX. We previously reported the inhibitory effects of various drugs on the OATP1B1-mediated uptake and their clinical relevance of drug-drug interaction (Hirano et al., 2006). However, this kind of systematic investigation for OATP1B3 has not been conducted. Therefore, the inhibitory effects of various drugs on the OATP1B3-mediated uptake were determined. Among several compounds we tested, the R values of cyclosporin A and rifampicin for OATP1B3 as well as OATP1B1 exceeded 2.0 (Table 1). To date, we have not been able to find a published report regarding a drug-drug interaction between FEX and cyclosporin A. Many clinical reports have been indicated that cyclosporin A increases the AUC of a variety of substrates of OATP transporters, particularly HMG-CoA reductase inhibitors (Shitara et al., 2005). Although cyclosporin A is known as a clinically relevant potent OATP1B1 inhibitor (Shitara et al., 2003), we showed that cyclosporin A can also potentially inhibit OATP1B3-mediated uptake. Accordingly, it is necessary to pay attention not only to the OATP1B1- but also the OATP1B3-mediated drug-drug interaction between FEX and cyclosporin A in clinical situations. Repetitive

administration of rifampicin reduced the plasma AUC of FEX in a previous clinical study (Hamman et al., 2001). This report apparently conflicts with the present results in which rifampicin inhibited the OATP1B3-mediated uptake. However, rifampicin is a well-known PXR-mediated inducer and increases the expression level of MDR1 in the small intestine (Schuetz et al., 1996). Therefore, in this case, repeated dosing of rifampicin increased the expression level of MDR1 in the small intestine, which masked its inhibitory effects on the OATP1B3-mediated uptake of FEX. This concept is supported by the recent report from Lam et al. (2006) indicating that drugs should be administered 1 day after final dosing of rifampicin to minimize potential inhibitory effects of OATP transporters in the induction study (Lam et al., 2006).

When comparing the K_i values for OATP1B1 with those for OATP1B3, except clarithromycin and ritonavir, K_i values for OATP1B1 and OATP1B3 were within the range of 5-fold difference, suggesting that the inhibitory potency of compounds for OATP1B1-mediated transport can be considered similar to that for OATP1B3-mediated transport. A specific inhibitor for each individual transporter is very useful for determining the contribution of each transporter to the overall membrane transport. Although EG and estrone-3-sulfate are

recognized as selective inhibitors for OATP1B1/OATP1B3 and OATP1B1/OATP2B1, respectively (Hirano et al., 2006), unfortunately, specific inhibitors for OATP1B3 have not yet been identified. Because of the high homology and overlapped substrate specificities between OATP1B1 and OATP1B3, the aid of *in silico* screening using a ligand-based drug design approach may be necessary to search for the selective inhibitors for OATP1B3 (Hirano et al., 2004).

Hirano et al. (2006) have indicated that cyclosporin A, rifampicin, clarithromycin and ritonavir (R value for OATP1B1 > 2.0) have a potential to interact with OATP1B1-mediated transport of pitavastatin in clinical situations (Hirano et al., 2006). Though the K_i values for OATP1B1-mediated uptake were determined by using pitavastatin as a substrate because of no significant uptake of FEX into OATP1B1-expressing HEK293 cells, considering the possible contribution of OATP1B1 as well as OATP1B3 to the hepatic uptake of FEX, these drugs may also affect the hepatic clearance of FEX. In order to avoid false-negative predictions of drug-drug interactions, the maximum plasma unbound concentration of inhibitors at the inlet to the liver was calculated using Eq. 3, which can overestimate these concentrations (Ito et al., 1998).

Therefore, in most cases, drug-drug interaction caused by inhibition of hepatic uptake of FEX might not occur in clinical situations.

In conclusion, both OATP1B1 as well as OATP1B3 are involved in the hepatic uptake of FEX and MRP2 can recognize FEX as a substrate. Among compounds we tested, cyclosporin A and rifampicin have the potential to inhibit the OATP1B1- and OATP1B3-mediated hepatic uptake of FEX at clinically relevant concentrations. However, most of the reported clinical drug-drug interactions cannot be simply explained by the inhibition of hepatic uptake of FEX and other mechanisms should be taken into account (e.g, inhibition of MDR1-mediated efflux in small intestine).

Acknowledgments

We would like to thank Dr. Junko Iida and Futoshi Kurotobi (Shimadzu Corporation, Kyoto, Japan) for technical support involving the LC/MS system.

We would also like to thank Atsushi Ose for providing valuable comments on the LC/MS system.

References

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos* **27**:866-871.

Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Afrime M and Batra V (2001) Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. *Clin Ther* **23**:451-466.

Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. *Pflugers Arch* **447**:653-665.

Hamman MA, Bruce MA, Haehner-Daniels BD and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. *Clin Pharmacol Ther* **69**:114-121.

Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. *Mol Pharmacol* **68**:800-807.

Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J Pharmacol Exp Ther* **311**:139-146.

Hirano M, Maeda K, Shitara Y and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. *Drug Metab Dispos* **34**:1229-1236.

Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K, Suzuki H and Sugiyama Y (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. *J Pharmacol Exp Ther* **290**:1324-1330.

Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacol Rev* **50**:387-412.

Lam JL, Shugarts SB, Okochi H and Benet LZ (2006) Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. *J Pharmacol Exp Ther* **319**:864-870.

Lemaire M and Tillement JP (1982) Role of lipoproteins and erythrocytes in the

in vitro binding and distribution of cyclosporin A in the blood. *J Pharm*

Pharmacol **34**:715-718.

Lippert C, Ling J, Brown P and burmaster S (1995) Mass balance and

pharmacokinetics of MDL 16,455A in the healthy, male volunteers. *Pharm*

Res (NY) **12**:S-390.

Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H and

Sugiyama Y (2005) Identification of the hepatic efflux transporters of

organic anions using double-transfected Madin-Darby canine kidney II

cells expressing human organic anion-transporting polypeptide 1B1

(OATP1B1)/multidrug resistance-associated protein 2,

OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance

protein. *J Pharmacol Exp Ther* **314**:1059-1067.

Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M and Fromm MF

(2005) Fexofenadine pharmacokinetics are associated with a

polymorphism of the SLCO1B1 gene (encoding OATP1B1). *Br J Clin*

Pharmacol **59**:602-604.

Ninomiya M, Ito K, Hiramatsu R and Horie T (2006) Functional analysis of

mouse and monkey multidrug resistance-associated protein 2 (Mrp2).

Drug Metab Dispos **34**:2056-2063.

Ninomiya M, Ito K and Horie T (2005) Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. *Drug Metab Dispos* **33**:225-232.

Sasaki M, Suzuki H, Ito K, Abe T and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). *J Biol Chem* **277**:6497-6503.

Schuetz EG, Beck WT and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. *Mol Pharmacol* **49**:311-318.

Selen A, Amidon GL and Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. *J Pharm Sci* **71**:1238-1242.

Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusahara H and Sugiyama Y (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. *Drug Metab Dispos* **33**:1477-1481.

Shimizu M, Uno T, Sugawara K and Tateishi T (2006a) Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. *Br J Clin Pharmacol* **61**:538-544.

Shimizu M, Uno T, Sugawara K and Tateishi T (2006b) Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. *Br J Clin Pharmacol* **62**:372-376.

Shitara Y, Itoh T, Sato H, Li AP and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. *J Pharmacol Exp Ther* **304**:610-616.

Shitara Y, Sato H and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol* **45**:689-723.

Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ and Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. *Clin Pharmacol Ther* **78**:191-201.

Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki

H and Sugiyama Y (2001) Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. *J Pharmacol Exp Ther* **298**:316-322.

Tahara H, Kusuhara H, Fuse E and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. *Drug Metab Dispos* **33**:963-968.

Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E and Sugiyama Y (2006) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. *Drug Metab Dispos* **34**:743-747.

Takekuma Y, Kakiuchi H, Yamazaki K, Miyauchi S, Kikukawa T, Kamo N, Ganapathy V and Sugawara M (2007) Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. *J Pharm Pharm Sci* **10**:71-85.

Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U and Lennernas H (2003) Multiple transport mechanisms involved in the intestinal absorption

and first-pass extraction of fexofenadine. *Clin Pharmacol Ther*

74:423-436.

Uno T, Shimizu M, Sugawara K and Tateishi T (2006) Lack of dose-dependent

effects of itraconazole on the pharmacokinetic interaction with

fexofenadine. *Drug Metab Dispos* **34**:1875-1879.

van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC

and Cameron DW (2006) Time-dependent interaction between

lopinavir/ritonavir and fexofenadine. *J Clin Pharmacol* **46**:758-767.

Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic

analysis program (multi) for microcomputer. *J Pharmacobiodyn*

4:879-885.

Yasui-Furukori N, Uno T, Sugawara K and Tateishi T (2005) Different effects of

three transporting inhibitors, verapamil, cimetidine, and probenecid, on

fexofenadine pharmacokinetics. *Clin Pharmacol Ther* **77**:17-23.

Footnotes

This study was supported by Industrial Technology Research Grant Program in 2006 from New Energy and Industrial Technology Development Organization (NEDO) of Japan and Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare for the Research on Regulatory Science of Pharmaceuticals and Medical Devices.

Legends for Figures

Figure 1. Time profiles for the transcellular transport of FEX and EG across MDCKII cell monolayers expressing OATP1B1 and/or MRP2

The transcellular transport of 5 μ M FEX (A-D) and 0.1 μ M EG (E-H) across MDCKII cell monolayers expressing OATP1B1 (B, F), MRP2 (C, G), both OATP1B1 and MRP2 (D, H) was compared with that across the vector-transfected control MDCKII cell monolayer (A, E). Open and closed circles represent the transcellular transport in the apical-to-basal and basal-to-apical directions, respectively. These data were obtained from three independent experiments and each experiment was performed in triplicate. Each point and vertical bar represents the mean and standard deviation. Where a vertical bar is not shown, the standard deviation was contained within the limits of the symbol.

Figure 2. Time profiles for the transcellular transport of FEX and EG across MDCKII cell monolayers expressing OATP1B3 and/or MRP2.

The transcellular transport of 5 μ M FEX (A-D) and 0.1 μ M EG (E-H) across MDCKII cell monolayers expressing OATP1B3 (B, F), MRP2 (C, G), both

OATP1B3 and MRP2 (D, H) was compared with that across the control MDCKII cell monolayer (A, E). Open and closed circles represent the transcellular transport in the apical-to-basal and basal-to-apical directions, respectively. These data were obtained from three independent experiments and each experiment was performed in triplicate. Each point and vertical bar represents the mean and standard deviation. Where a vertical bar is not shown, the standard deviation was contained within the limits of the symbol.

Figure 3. Inhibitory effects of various drugs on the OATP1B3-mediated uptake of FEX

The OATP1B3-mediated uptake of FEX (10 μ M) was determined in the absence or presence of inhibitors; (A) cyclosporin A, (B) rifampicin, (C) fluconazole, (D) itraconazole, (E) ketoconazole, (F) clarithromycin, (G) erythromycin, (H) azithromycin, (I) ritonavir, (J) lopinavir, (K) diltiazem, (L) verapamil, (M) omeprazole, and (N) cimetidine using OATP1B3-expressing HEK293 cells. These data were obtained from three independent experiments and each experiment was performed in triplicate. Each point and vertical bar represents the mean and standard deviation. Where a vertical bar is not shown,

the standard deviation was contained within the limits of the symbol. Each solid line represents the fitting curve obtained by non-linear regression analysis.

Table 1. Comparison of K_i values of inhibitors for OATP1B1-mediated uptake of pitavastatin and OATP1B3-mediated uptake of FEX

Inhibitor	Dosage (mg)	I_{max} (μ M)	$I_{in,max}$ (μ M)	f_u	OATP1B3		OATP1B1	
					K_i (μ M)	R	K_i (μ M) ^{*5}	R
cyclosporin A	100	0.596	5.76	0.10^{*1}	0.573 ± 0.172	2.01	0.242 ± 0.029	3.55
rifampicin	600^{*2}	7.90^{*2}	53.2	0.11^{*2}	1.45 ± 0.28	5.03	0.477 ± 0.030	13.3
fluconazole	100	8.62	28.9	0.89^{*2}	>100	<1.26	>100	<1.26
itraconazole	100	0.0792	8.88	0.002^{*2}	>30	1.00	>100	1.00
ketoconazole	200^{*2}	3.20^{*2}	26.6	0.01^{*2}	18.5 ± 3.0	1.01	19.2 ± 3.9	1.01
clarithromycin	400	1.86	35.1	0.54^{*2}	53.6 ± 15.9	1.42	8.26 ± 0.54	3.29
erythromycin	200	1.12	18.0	0.16^{*2}	38.3 ± 7.7	1.08	11.4 ± 2.1	1.25
azithromycin	1200	0.881	100	0.84	161 ± 7.7	1.52	n.d. ^{*6}	
ritonavir	800	28.5	97.4	0.02^{*2}	5.64 ± 1.39	1.35	0.781 ± 0.048	3.49
lopinavir	400	15.2	54.8	0.015	18.4 ± 7.2	1.04	n.d. ^{*6}	
probenecid	2000^{*3}	52.0^{*3}	487	0.10^{*2}	$130 \pm 40^{*4}$	1.37	76.2 ± 7.1	1.64
diltiazem	100	0.0536	15.0	0.22^{*2}	193 ± 112	1.03	>100	<1.03
verapamil	80	0.190	11.1	0.10^{*2}	89.5 ± 52.9	1.01	51.6 ± 15.9	1.02
omeprazole	20	1.18	4.77	0.03	53.9 ± 14.3	1.00	n.d. ^{*6}	
cimetidine	200	2.75	52.0	0.81^{*2}	>100	<1.42	>300	<1.14

The K_i values are expressed as the mean \pm computer-calculated S.D.

The inhibitors, which are shown by boldface, increased the AUC of the plasma AUC in the previous clinical studies. Data for dosages, I_{max} , and f_u are from

product information of each drug except the data with footnotes. R and $I_{in,max}$ values are calculated according to (Eq. 2) and (Eq.3), respectively (see **Materials and Methods**).

*1 Data for protein unbound fraction of cyclosporin A was from a previous report (Lemaire and Tillement, 1982).

*2 These data are from Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th Edition.

*3 Data for dosages, I_{max} of probenecid from a previous report (Selen et al., 1982).

*4 K_i values of probenecid were previously determined (Tahara et al., 2006).

*5 K_i values of inhibitors for the OATP1B1-mediated uptake of pitavastatin were previously determined (Hirano et al., 2006).

*6 Not determined.

Figure 1




Figure 2




Figure 3

